Iclaprim, 316
ICU.SeeIntensive care unit (ICU)
IDSA.SeeInfectious Diseases Society of America
(IDSA)
IDSA guidelines for CDI, 282
IE.SeeInfective endocarditis (IE)
IgM.SeeImmunoglobulin M (IgM)
IHI.SeeInstitute for Healthcare Improvement (IHI)
IL.SeeInterleukins (IL)
ILD.SeeInterstitial lung disease (ILD)
ILI.SeeInfluenza-like illnesses (ILI)
Imatinib mesylate, 477
Imipenem, 190, 544
Immune reconstitution disease (IRD), 422
Immune system
glucocorticoid therapy, effects of, 377
Immunoglobulin M (IgM), 29
Immunology
miliary tuberculosis, 422
Immunoprophylaxis
HiB vaccine, 355
influenza vaccine, 355
meningococcal vaccine, 355
pneumococcal vaccine, 354–355
Impetigo, 297
In-111.SeeIndium-111 (In-111)
Indium-111 (In-111), 261
Infectious disease consultation, 6
Infectious Diseases Society of America (IDSA), 187,
280, 487
Infective endocarditis (IE)
antibiotic therapy, 240–241
organism directed, 241–245
anticoagulation in, 246
differential diagnosis
history, 232
laboratory/imaging tests, 232–235
physical examination, 232
epidemiology, 223
cardiac predisposing factors, 224–227
clinical presentation, 228–229
extracardiac predisposing factors, 227–228
prosthetic valve endocarditis, 229–231
fungal, 245–246
microbiology, 218–223
mimics of, 237–238
nonantibiotic therapy, 238–240
presumptive clinical diagnosis, 235–237
prophylaxis of, 246–249
rabbit model of, 224
in SOT recipients, 404
Infiltrative diseases, 351
Inflammatory bowel disease (IBD), 84, 377, 400
Infliximab, 380
Influenza, 181
anti-TNF therapy and, 382
infection, in SOT recipients, 396
Influenza-like illnesses (ILI), 498
Influenza pneumonia, 97
Influenza vaccine, 355
Inguinal lymphadenopathy, physical findings
diagnostic features, 55
noninfectious mimics, 55
PE findings, 55
INH.SeeInitial phase of isoniazid (INH)
Inhalational anthrax, 439
Initial phase of isoniazid (INH), 427
Injury
pathophysiology of, 524–525
Injury Severity Score, 182
INR.SeeInternational normalized ratio (INR)
Inspiratory crackles, physical findings
diagnostic features, 57
noninfectious mimics, 57
PE findings, 57
Inspiratory stridor, physical findings
diagnostic features, 56
enlargement and tenderness, 56
noninfectious mimics, 56
Intensive care unit (ICU), 487, 542
adult
epidemiology of CA-MRSA, 107
epidemiology of HA-MRSA, 104–105
infections caused by CA-MRSA, 104
infections caused by HA-MRSA, 104
risk factors for acquisition of VRE
in, 113–114
type of infection caused by VRE, 112
control measures for MRSA in, 111
control measures for VRE in, 119
epidemiology of VRE in
sources of VRE, 113
transmission of VRE, 113
neonatal
epidemiology of CA-MRSA, 107
epidemiology of HA-MRSA, 106
infections caused by CA-MRSA, 104
infections caused by HA-MRSA, 104
risk factors for acquisition of VRE in, 114
type of infection caused by VRE in, 113
prevention and control of MRSA in
contact precautions, 108
cost effectiveness, 110, 112
decolonization.SeeDecolonization
decontamination of environment, 108
hand hygiene, 108–109
screening patients for colonization, 108
prevention and control of VRE in
antimicrobial agents, 117–118
contact precautions, 116
culture surveillance, 116
decontamination of environment, 117
hand hygiene, 117
risk factors for acquisition of VRE in, 113–115
Interleukins (IL), 351
International normalized ratio (INR), 546
International Society of Travel Medicine
(ISTM), 322
Interstitial keratitis, 67
Interstitial lung disease (ILD), 99568 Index